About this trial
This study is a single-center, randomized, double-blind, placebo-controlled clinical trial investigating a pharmacological intervention for aging. Its primary objective is to evaluate the efficacy of NMN while ensuring the safety of oral administration, with the aim of identifying effective strategies to delay aging and improve the quality of life in the elderly population. The main outcomes of this study are to characterize the patterns of NMN efficacy across different populations and to identify sensitive biomarkers that reflect responsiveness to the intervention.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Local residents of Quzhou or living in Quzhou for over ten years.
age 40-50 and 60-70 years old, no major bad habits.
Gender unlimited.
in good health and has not undergone major surgery within half a year.
Disqualifiers
Alcoholism, heavy smoking (more than 5 packs/day, 20 cigarettes per pack), drug abuse or substance abuse.
Participants are conducting other clinical trials or using any research drugs or equipment for treatment within 30 days before enrollment (including but not limited to aspirin, metformin, resveratrol, vitamin C, etc.).
Obesity (bmi more than 30).
Pregnant/lactating women.
Trial design
Parallel
Treatments tested in this trial
NMN
Dietary supplementNMN Arm participants took one capsule (containing 350mg NMN or placebo) with breakfast daily for one year.
placebo
Dietary supplementPlacebo arm participants took one capsule (appearance and odor are the same as NMN) with breakfast daily for one year.
Treatment groups
8
Treatment groupsSee each treatment group below.
Trial outcomes
Primary outcomes
Comprehensive evaluation of NMN in reducing biological age
Change in biological age from baseline to 12 months, quantified using predefined multi-layer aging clock(s). Biological age will be assessed using the following measures: 1. Transcriptomic age (years) 2. DNA methylation age (years) 3. Proteomic age (years) 4. Metabolomic age (years) 5. Phenotypic age (years) The primary endpoint will be defined as: Change from baseline to 12 months in a prespecified composite biological age score, derived from the above aging clocks using a predefined integration method (e.g., standardized z-score aggregation or principal component-based integration). A reduction in biological age is defined as a decrease in the composite biological age score.
Secondary outcomes
Composite through clinical physical examination data, behavioral indicators and multilevel omics data, to discover new sensitive biomarkers for evaluating aging.
NMN intervention-associated changes will be evaluated across predefined domains: 1. Clinical examination parameters, such as: 1. Bone mineral density (g/cm²) 2. Pulmonary function, including FEV1 (L), FVC (L), and FEV1/FVC (%) Each parameter will be analyzed individually. 2. Functional performance measures, such as: 1. Grip strength (kg) 2. Purdue Pegboard Test completion time (s) Improvement is defined as an increase in grip strength and a decrease in completion time. 3. Inflammatory and clinical biomarkers, such as: Circulating inflammatory markers (e.g., IL-6 \[pg/mL\], CRP \[mg/L\]) Improvement is defined as a reduction in these markers. 4. Multi-omics-derived aging biomarkers, such as: Gene expression, proteomic, and metabolomic profiles related to metabolism, immunity, and aging. These measures will be summarized using: Predefined composite aging scoresm, biological ages, or principal component-based or pathway-level summaries, depending on the analysis framework.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
People's Hospital of Quzhou
Lead sponsor
Beijing Institute of Genomics, Chinese Academy of Sciences
Collaborator
Institute of Zoology, Chinese Academy of Sciences
Collaborator